Targeted lung cancer screening in the age of immunotherapies and targeted therapies – an economic evaluation for Australia
Jacqueline Roseleur, Jonathan Karnon, Harry de Koning, Vivienne Milch, Katrina Anderson, Jacqui Real, Dorothy Keefe, Kevin ten Haaf · 2024
Read Targeted lung cancer screening in the age of immunotherapies and targeted therapies – an economic evaluation for Australia by Jacqueline Roseleur, Jonathan Karnon, Harry de Koning, Vivienne Milch, Katrina Anderson, Jacqui Real, Dorothy Keefe, Kevin ten Haaf (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11626775.txt.
Description
Jacqueline Roseleur and co-authors price a national lung screening program for Australia. Their 2024 economic study models targeted scans for heavy smokers, asking how modern cancer drugs change the sums that earlier, simpler models produced.
The recommended plan scans current and recent former smokers with at least thirty pack-years, every two years from fifty to seventy. It prevents about sixty-two lung deaths per hundred thousand people at a cost the authors judge acceptable per healthy year gained. New therapies cut screening's added costs but also shrank its added benefit, since treated patients live longer anyway. Netting out, screening looked slightly more cost-effective with modern therapy priced in. The analysis informed the national advisory body's recommendation.
Catalog record
| CREATOR | Jacqueline Roseleur, Jonathan Karnon, Harry de Koning, Vivienne Milch, Katrina Anderson, Jacqui Real, Dorothy Keefe, Kevin ten Haaf |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |